VG Life Sciences Inc.
VGLS
$0.00
$0.000.00%
| 09/30/2015 | 06/30/2015 | 03/31/2015 | 12/31/2014 | 09/30/2014 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -44.81% | -47.03% | -33.09% | 5.77% | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -52.47% | -50.25% | -36.21% | 6.04% | -- |
| Operating Income | 52.47% | 50.25% | 36.21% | -6.04% | -- |
| Income Before Tax | 51.29% | 53.29% | 36.52% | 16.78% | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 51.29% | 53.29% | 36.52% | 16.78% | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -35.82% | -36.65% | -40.38% | -43.70% | -- |
| Net Income | 51.38% | 53.38% | 36.49% | 16.56% | -- |
| EBIT | 52.47% | 50.25% | 36.21% | -6.04% | -- |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 85.35% | 84.86% | 74.43% | 73.51% | -- |
| Normalized Basic EPS | 85.39% | 84.87% | 74.37% | 73.45% | -- |
| EPS Diluted | 85.35% | 84.86% | 74.43% | 73.51% | -- |
| Normalized Diluted EPS | 85.39% | 84.87% | 74.37% | 73.45% | -- |
| Average Basic Shares Outstanding | 187.77% | 191.81% | 207.04% | 246.03% | -- |
| Average Diluted Shares Outstanding | 187.77% | 191.81% | 207.04% | 246.03% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
